Form 4: Ginkgo Bioworks Director Sri Kosuri Reports RSU Vesting and New Stock Option Grant

Ginkgo Bioworks Holdings, Inc. Director Sri Kosuri has reported the vesting of 24,067 restricted stock units and the acquisition of 34,375 new stock options, as disclosed in a recent SEC Form 4 filing.

Summary

• Sri Kosuri, a Director at Ginkgo Bioworks Holdings, Inc. (DNA), reported changes in beneficial ownership.
• On June 11, 2025, 24,067 restricted stock units (RSUs) vested, converting into an equal number of Class A Common Stock shares. These RSUs were granted on November 6, 2024, and vested fully the day before the company's Annual Meeting of Shareholders, contingent on continued service.
• On June 12, 2025, Mr. Kosuri was granted 34,375 stock options with an exercise price of $9.29 per share.
• These new stock options will vest in substantially equal installments over three years, becoming fully vested on the third anniversary of the grant date (June 12, 2028), provided Mr. Kosuri continues as a Non-Employee Director.
• The new stock option grant is in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 12, 2025.

Sentiment

Score: 5

Explanation: This is a routine SEC Form 4 filing detailing director compensation, which is neutral in sentiment. It reflects standard corporate governance practices for incentivizing directors.

Positives

• Director Sri Kosuri received 24,067 shares of Class A Common Stock from the vesting of restricted stock units, increasing his direct ownership.
• The grant of 34,375 new stock options aligns the director's incentives with long-term company performance, with an exercise price of $9.29.

Future Outlook

The newly granted stock options will vest in substantially equal installments over three years, with full vesting expected on June 12, 2028, contingent on the director's continued service. This indicates a long-term incentive structure for the director.

Industry Context

This filing reflects standard equity compensation practices for non-employee directors in the biotechnology or synthetic biology industry, aiming to align director interests with long-term shareholder value.

Comparison to Industry Standards

• The compensation structure, involving RSUs and stock options with multi-year vesting, is a common practice for non-employee directors in publicly traded companies, particularly in growth-oriented sectors like biotechnology. Specific comparable companies or projects are not detailed in this filing, as it focuses on an individual's transaction.

Corporate Governance

Related Party Transactions

• The vesting of RSUs and the grant of stock options to a director constitute related party transactions as they involve compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The compensation structure aims to align the director's interests with long-term shareholder value. The issuance of shares from RSU vesting and potential future exercise of options could lead to minor dilution over time.

Next Steps

• The 34,375 stock options granted on June 12, 2025, are scheduled to vest in substantially equal installments on each of the first three anniversaries of the grant date, subject to continued service.

Key Dates

Keywords

Ginkgo Bioworks Holdings Inc, DNA, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, RSU Vesting, Stock Options, Equity Compensation, Corporate Governance, Sri Kosuri